N-Methyl-1-deoxynojirimycin (MOR-14), an α-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction

[1]  M. Arai,et al.  Role of protein kinase C in the reduction of infarct size by N‐methyl‐1‐deoxynojirimycin, an α‐1,6‐glucosidase inhibitor , 2001, British journal of pharmacology.

[2]  B. Jugdutt,et al.  Enhanced Expression of Angiotensin II Type 2 Receptor, Inositol 1,4,5-Trisphosphate Receptor, and Protein Kinase C&egr; During Cardioprotection Induced by Angiotensin II Type 2 Receptor Blockade , 2000, Hypertension.

[3]  M. Arai,et al.  N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly reduced infarct size in rabbit hearts. , 1998, Circulation.

[4]  HisatoTakatsu,et al.  N-Methyl-1-Deoxynojirimycin (MOR-14), an α-Glucosidase Inhibitor, Markedly Reduced Infarct Size in Rabbit Hearts , 1998 .

[5]  M. Arai,et al.  Infarct Size-Reducing Effect of Ischemic Preconditioning Is Related to α1b-Adrenoceptors But Not to α1a-Adrenoceptors in Rabbits , 1997 .

[6]  P. Ping,et al.  Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. , 1997, Circulation research.

[7]  V. P. Chacko,et al.  Role of preischemic glycogen depletion in the improvement of postischemic metabolic and contractile recovery of ischemia-preconditioned rat hearts. , 1997, Circulation.

[8]  後藤真彦.  Role of bradykinin in protection of ischemic preconditioning in rabbit hearts(家兎心のプレコンディシュニングにおけるブラジキニンの役割) , 1997 .

[9]  G. Pagano,et al.  Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. , 1995, Diabete & metabolisme.

[10]  M. Hori,et al.  Effect of angina pectoris on myocardial protection in patients with reperfused anterior wall myocardial infarction: retrospective clinical evidence of "preconditioning". , 1995, Journal of the American College of Cardiology.

[11]  S. Sasayama,et al.  Superoxide dismutase and N-2-mercaptopropionyl glycine attenuate infarct size limitation effect of ischaemic preconditioning in the rabbit. , 1994, Cardiovascular research.

[12]  J. Downey,et al.  Preconditioning protects ischemic rabbit heart by protein kinase C activation. , 1994, The American journal of physiology.

[13]  B. Hulin.  New hypoglycaemic agents. , 1994, Progress in medicinal chemistry.

[14]  R. Sievers,et al.  Loss of Myocardial Protection After Preconditioning Correlates With the Time Course of Glycogen Recovery Within the Preconditioned Segment , 1993, Circulation.

[15]  R. Kloner,et al.  The transient nature of the effect of ischemic preconditioning on myocardial infarct size and ventricular arrhythmia. , 1992, American heart journal.

[16]  G. Gross,et al.  Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. , 1992, Circulation research.

[17]  R. Jennings,et al.  Energy metabolism in preconditioned and control myocardium: effect of total ischemia. , 1991, Journal of molecular and cellular cardiology.

[18]  C. Kawai,et al.  Ischemic Preconditioning Preserves Creatine Phosphate and Intracellular pH , 1991, Circulation.

[19]  J. Downey,et al.  Protection Against Infarction Afforded by Preconditioning is Mediated by A1 Adenosine Receptors in Rabbit Heart , 1991, Circulation.

[20]  J. Downey,et al.  Inhibition of protein synthesis does not block myocardial protection afforded by preconditioning. , 1990, The American journal of physiology.

[21]  R. Jennings,et al.  Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. , 1990, Circulation research.

[22]  W. Schaper,et al.  Ischemic preconditioning reduces infarct size in swine myocardium. , 1990, Circulation research.

[23]  M. Bollen,et al.  The antiglycogenolytic action of 1-deoxynojirimycin results from a specific inhibition of the alpha-1,6-glucosidase activity of the debranching enzyme. , 1989, European journal of biochemistry.

[24]  G. Radda,et al.  Determination of buffering capacity of rat myocardium during ischemia. , 1988, Biochimica et biophysica acta.

[25]  M. Bollen,et al.  1-Deoxynojirimycin and related compounds inhibit glycogenolysis in the liver without affecting the concentration of phosphorylase a. , 1988, Biochemical pharmacology.

[26]  R. Jennings,et al.  Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. , 1986, Circulation.

[27]  J. R. Neely,et al.  Role of Glycolytic Products in Damage to Ischemic Myocardium: Dissociation of Adenosine Triphosphate Levels and Recovery of Function of Reperfused Ischemic Hearts , 1984, Circulation research.

[28]  Hans Ulrich Bergmeyer,et al.  Methods of Enzymatic Analysis , 2019 .